Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697290 | 0.91 | ALDH1A1 (0.41) | TP53MAPTLMNACSNK1DHKDC1 | |
| SCHEMBL21246013 | 0.86 | LMNA (0.41) | TP53MAPTLMNACSNK1DHKDC1 | |
| SCHEMBL20689606 | 0.86 | HPGD (0.36) | TP53MAPTLMNACSNK1DALDH1A1 | |
| SCHEMBL20689010 | 0.86 | TYK2 (0.44) | LMNACSNK1DHPGDCYP1A1TYK2 | |
| SCHEMBL20689148 | 0.86 | CSNK1D (0.34) | TP53MAPTLMNACSNK1DHKDC1 | |
| SCHEMBL20689569 | 0.84 | LMNA (0.41) | MAPTLMNACSNK1DHKDC1ALDH1A1 | |
| SCHEMBL20688901 | 0.84 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EPOLBTYK2 | |
| SCHEMBL20678811 | 0.84 | KDM4E (0.41) | MAPTLMNAALDH1A1HPGDKDM4E | |
| SCHEMBL20688967 | 0.83 | KDM4E (0.41) | TP53MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL20689492 | 0.82 | DPP4 (0.30) | ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885MAPT 1236/4885LMNA 2078/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TP53 2843/4885MAPT 1236/4885LMNA 2078/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885MAPT 1236/4885LMNA 2078/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TP53 2843/4885MAPT 1236/4885LMNA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.